Free Trial
NASDAQ:INZY

Inozyme Pharma Q4 2023 Earnings Report

Inozyme Pharma EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Inozyme Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inozyme Pharma Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 12, 2024
Conference Call Time
8:00AM ET

Inozyme Pharma Earnings Headlines

Inozyme Pharma Inc News (INZY) - Investing.com
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Inozyme Pharma Inc Ordinary Shares
See More Inozyme Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inozyme Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inozyme Pharma and other key companies, straight to your email.

About Inozyme Pharma

Inozyme Pharma (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

View Inozyme Pharma Profile

More Earnings Resources from MarketBeat